NEW YORK, July 21, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Baxter International Inc. (NYSE: BAX), The Cooper Companies, Inc. (NYSE: COO), Waters Corporation (NYSE: WAT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4932-100free.
Covidien plc Analyst Notes
On July 16, 2014, Covidien plc announced that its Board of Directors has declared a quarterly cash dividend of $0.32 per ordinary share. The Company informed that the dividend is payable on August 19, 2014, to shareholders of record as of July 29, 2014. The full analyst notes on Covidien are available to download free of charge at:
http://www.analystsreview.com/Jul-21-2014/COV/report.pdf
Baxter International Inc. Analyst Notes
On July 14, 2014, Baxter International Inc. (Baxter) announced its voluntary recall of four lots of intravenous (IV) solutions to the hospital/user level due to the presence of particulate matter identified as cellulosic fibers and/or plastics. According to Baxter, the products affected by the recall are - 0.9% Sodium Chloride 100 mL (Quad Pack), Lot # P298190; 0.9% Sodium Chloride 100 mL MINI-BAG Plus Lot # P308650; 0.9% Sodium Chloride, 50 mL (Single Pack), Lot # P309187; and Highly Concentrated Potassium Chloride Injection, 20 mEq/50 mL, VIAFLEX Plus Container, Lot # P309476. The Company informed that over a period of six months it has received four complaints from customers whose visual inspection identified the appearance of visible particulate matter before administration to a patient. The full analyst notes on Baxter are available to download free of charge at:
http://www.analystsreview.com/Jul-21-2014/BAX/report.pdf
The Cooper Companies, Inc. Analyst Notes
On July 10, 2014, The Cooper Companies, Inc. announced that its Board of Directors has approved and declared a semi-annual dividend of $0.03 per share. The dividend is payable on August 6, 2014, to stockholders of record as of July 24, 2014. The full analyst notes on Cooper are available to download free of charge at:
http://www.analystsreview.com/Jul-21-2014/COO/report.pdf
Waters Corporation Analyst Notes
On July 9, 2014, Waters Corporation (Waters) announced an agreement with the Chinese Pharmacopoeia Commission (ChP) to establish a Joint Open Laboratory. Waters expects the Joint Open Laboratory to open before the end of 2014, and will focus on in-depth research of pharmacopoeia standards, development of testing methods, methods validations, and basic and advanced technical training of pharmacopoeia detection methods. "I am confident that this new Joint Open Laboratory will make positive contributions to assuring drug quality control in China, it will quickly become an international leader in the field of traditional Chinese pharmaceutical standards," said Art Caputo, President of Waters Division. The full analyst notes on Waters are available to download free of charge at:
http://www.analystsreview.com/Jul-21-2014/WAT/report.pdf
CareFusion Corporation Analyst Notes
On July 10, 2014, CareFusion Corporation (CareFusion) announced that it intends to release its Q4 FY 2014 and FY 2014 results (period ended June 30, 2014) on August 7, 2014, after the close of trading on the NYSE. On the same day, the Company has also scheduled a conference call at 2:00 p.m. PDT / 5:00 p.m. EDT to discuss the results and provide future guidance. CareFusion informed that a replay of the conference call will also be available from 6 p.m. PDT (9 p.m. EDT) on August 7, 2014 through 11:59 p.m. PDT on August 14, 2014. The full analyst notes on CareFusion are available to download free of charge at:
http://www.analystsreview.com/Jul-21-2014/CFN/report.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.analystsreview.com
SOURCE Analysts Review
